RC
CCCC icon

RegentAtlantic Capital’s C4 Therapeutics CCCC Stock Holding History

RegentAtlantic Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$111K Buy
12,695
+1,315
+12% +$13.7K ﹤0.01% 653
2022
Q2 		$86K Hold
11,380
– – ﹤0.01% 662
2022
Q1 		$276K Buy
11,380
+428
+4% +$10.4K 0.01% 587
2021
Q4 		$353K Sell
10,952
-1,626
-13% -$64.3K 0.01% 533
2021
Q3 		$562K Sell
12,578
-1,906
-13% -$81.6K 0.02% 406
2021
Q2 		$548K Sell
14,484
-1,510
-9% -$54.1K 0.02% 406
2021
Q1 		$592K Buy
+15,994
New +$636K 0.02% 355

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

RegentAtlantic Capital's CCCC Position: Q3 2022 in Review

RegentAtlantic Capital increased its C4 Therapeutics (CCCC) stake by 12% in Q3 2022, buying an estimated $13.7K and bringing the position to 12,695 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #653.

RegentAtlantic Capital first reported a position in CCCC in Q1 2021 and has held it in 7 quarters since. The position peaked at $592K in Q1 2021. 114 funds tracked by Wall St. Rank hold CCCC as of Q3 2022.

  • RegentAtlantic Capital held 12,695 shares of C4 Therapeutics worth $111K as of Q3 2022.
  • RegentAtlantic Capital bought 1,315 C4 Therapeutics shares in Q3 2022, an estimated $13.7K.
  • C4 Therapeutics made up ﹤0.01% of RegentAtlantic Capital's portfolio in Q3 2022, its #653 holding.
  • RegentAtlantic Capital first reported a position in C4 Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • RegentAtlantic Capital's C4 Therapeutics position peaked at $592K in Q1 2021.
  • 114 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2022.

Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.